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SYSTEMATIC REVIEW AND META-ANALYSIS
Do Women Require Less Permanent 
Pacemaker After Transcatheter Aortic 
Valve Implantation? A Meta- Analysis and 
Meta- Regression
Justine M. Ravaux , MD; Michele Di Mauro , MD, PhD, MSc Biostat; Kevin Vernooy , MD, PhD; 
Arnoud W. Van’t Hof , MD, PhD; Leo Veenstra, MD; Suzanne Kats, MD, PhD; Jos G. Maessen, MD, PhD; 
Roberto Lorusso, MD, PhD
BACKGROUND: Limited clinical evidence and literature are available about the potential impact of sex on permanent pacemaker 
implantation (PPI) after transcatheter aortic valve implantation (TAVI). The aim of this work was to evaluate the relationship 
between sexes and atrioventricular conduction disturbances requiring PPI after TAVI.
METHODS AND RESULTS: Data were obtained from 46 studies from PubMed reporting information about the impact of patient 
sex on PPI after TAVI. Total proportions with 95% Cls were reported. Funnel plot and Egger test were used for estimation of 
publication bias. The primary end point was 30- day or in- hospital PPI after TAVI, with odds ratios and 95% CIs extracted. A 
total of 70 313 patients were included, with a cumulative proportion of 51.5% of women (35 691 patients; 95% CI, 50.2– 52.7). 
The proportion of women undergoing TAVI dropped significantly over time (P<0.0001). The cumulative PPI rate was 15.6% 
(95% CI, 13.3– 18.3). The cumulative rate of PPI in women was 14.9% (95% CI, 12.6– 17.6), lower than in men (16.6%; 95% 
CI, 14.2– 19.4). The risk for post- TAVI PPI was lower in women (odds ratio, 0.90; 95% CI, 0.84– 0.96 [P=0.0022]). By meta- 
regression analysis, age (P=0.874) and ventricular function (P=0.302) were not significantly associated with PPI among the 
sexes. Balloon- expandable TAVI significantly decrease the advantage of women for PPI, approaching the same rate as in men 
(P=0.0061).
CONCLUSIONS: Female sex is associated with a reduced rate of PPI after TAVI, without influence of age or ventricular function. 
Balloon- expandable devices attenuate this advantage in favor of women. Additional investigations are warranted to elucidate 
sex- based differences in developing conduction disturbances after TAVI.
Key Words: permanent pacemaker ■ sex ■ transcatheter aortic valve implantation ■ women
Transcatheter aortic valve implantation (TAVI) is a well- established therapeutic approach for patients with aortic stenosis at high and in-
termediate surgical risk.1 Considerable advances 
in procedural techniques tend to extent TAVI in-
dications to patients with a lower surgical risk.2 
However, atrioventricular conduction disturbances 
requiring PPI after TAVI continue to impact the ben-
efit of this approach.3,4 Sex- specific variations in the 
electrophysiological structure of the heart or other 
hormonal processes may cause differences in post- 
operative conduction disturbances leading to PPI.5 
A better patient selection and identification of pre-
operative risk factors for progression of conduction 
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disturbances and subsequently PPI seem decisive 
to extent TAVI indications.6 Current data about the 
impact of sex on PPI after TAVI remain controversial.7 
Female patients undergoing TAVI tend to have bet-
ter outcomes than men8,9 but specific investigations 
about PPI after TAVI according to sex have not been 
conducted: meta- analyses reporting on sex equality 
after TAVI do not often conclude about PPI accord-
ing sex.8– 10 Siontis and colleagues11 identified male 
sex as preprocedural predictor of PPI after TAVI but 
a recent meta- analysis showed that post- operative 
need for PPI was similar across sexes.8 Women tend 
to have less comorbidities than men at baseline10,12,13 
but PPI creates more complications to women than 
men: pneumothorax and pocket haematoma after 
PPI are significantly more frequent in female pa-
tients.14 Enhancing preventive measures for post- 
operative PPI, optimizing management of conduction 
disturbances post- TAVI and implementing data on 
sex differences in PPI after TAVI in clinical practice 
appear to be crucial.15,16 Therefore, we performed a 
meta- analysis of published studies that reported sex- 
specific data on PPI after TAVI aiming to clarify the 
independent prognostic role of sex in patients under-
going PPI after TAVI.
METHODS
The authors declare that all supporting data are availa-
ble within the article and its online supplementary files.
Research Strategy
This meta- analysis was performed in accordance 
with the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) Guidelines 
and the Cochrane Collaboration, Quality of Reporting 
Meta- analyses (QUOROM). A broad, computerized lit-
erature search was performed to identify all relevant 
studies from PubMed database. The PubMed data-
base was searched entering the following keywords: 
"Pacemaker, Artificial" [Mesh] OR pacemaker implan-
tation AND "Transcatheter Aortic Valve Replacement" 
[Mesh] OR transcatheter aortic valve replacement AND 
"Female Sex" [Mesh] OR female gender. We restricted 
the research to publications in English language. Last 
access on database was on June 1, 2020. The search 
was limited to studies in human recipients.
Eligibility Criteria and Studies Selection
Review inclusion criteria were: patients aged 
>18  years (I), series with >250 patients (II) and re-
ports providing a description of pacemaker status 
of the treated population (III). Furthermore, articles 
with no possible extraction of data sex were ex-
cluded. Systematic review and meta- analyses were 
not taken into account. Studies describing cardiac 
surgery procedures were excluded. We restricted the 
research to English publications.
Data Extraction
All potentially relevant studies were reviewed in de-
tails to check their adhesion to the inclusion criteria. 
A total of 877 records were initially screened at the 
title and abstract level, with 222 papers fully reviewed 
for eligibility. Title and abstracts of all retrieved arti-
cles were independently reviewed by two research-
ers (J.R. and M.D.M.) to identify studies fulfilling the 
inclusion criteria. Controversial findings were solved 
by the intervention of a third reviewer (R.L.). There 
were no duplicate data. Ultimately, 46 studies were 
identified and provided data for the research analy-




• Permanent pacemaker implantation (PPI) re-
mains a frequent complication after transcath-
eter aortic valve implantation.
• A discriminative impact of sex has been ob-
served in transcatheter aortic valve implantation 
outcomes, in favor of women, without specifi-
cally addressing the issue of postoperative PPI 
according to patient sex.
• This meta- analysis involving 35  691 women 
among a cohort of 70 313 patients is the first 
study to demonstrate a positive impact of female 
sex on postoperative PPI- related complication 
after transcatheter aortic valve implantation, 
with a beneficial risk reduction of 10%, indepen-
dently of age or ventricular function.
What Are the Clinical Implications?
• Valve type may play an additional role; using a 
balloon- expandable valve in women increases 
the risk of PPI, reaching the same probability of 
PPI as in male patients.
• Further studies are required to understand the 
underlying mechanisms of postoperative con-
duction disturbances leading to PPI according 
to patient sex.
Nonstandard Abbreviations and Acronyms
PPI permanent pacemaker implantation




 http://ahajournals.org by on O
ctober 18, 2021
J Am Heart Assoc. 2021;10:e019429. DOI: 10.1161/JAHA.120.019429 3
Ravaux et al Women and Pacemaker Implantation After TAVI
Statistical Analysis
Calculation of an overall proportion from stud-
ies reporting a single proportion was performed 
using a meta- analytic approach by means of 
metaprop function of meta- package in RStudio. A 
logit- transformation was performed as suggested 
by Warton and Hui17 to calculate CIs for individual 
study results, Clopper- Pearson approach was used; 
DerSimonian- Laird estimator was used to estimate 
the between- study variance.18 Total proportion with 
95% Cl was reported. Funnel plot and Egger test 
were used for estimation of publication bias. Primary 
endpoint was 30- day or in- hospital PPI after TAVI, 
with odds ratios (ORs) and 95% CIs extracted from 
46 studies. Statistical pooling of OR was performed 
using a random effect model with 95% CIs. Forest 
plots were used to plot the effect size, either for each 
study or overall. We calculated the I2 statistics (0– 
100%) to explain the between- study heterogeneity, 
with I2≤25% suggesting more homogeneity, 25% 
< I2≤75% suggesting moderate heterogeneity, and 
I2>75% suggesting high heterogeneity.19,20 If the null 
hypothesis was rejected, a random effects model was 
used to calculate pooled effect estimates. If the null 
hypothesis was not rejected, a fixed effects model 
was used to calculate pooled effect estimations18; 
95% CI was also reported. Forest plots were used 
to plot the effect size, either for each study or overall. 
Publication bias was evaluated by graphical inspec-
tion of funnel plot; estimation of publication bias was 
quantified by means of Egger linear regression test.21 
In case of moderate or high heterogeneity, influence 
analysis was performed with different approaches. 
Baujat plot22 and leave- one- out sensitivity analysis 
were performed by iteratively removing one study at 
a time to confirm that our findings were not driven 
by any single study. Meta- regression analysis was 
performed, reporting results as P value. One study 
removed analysis was performed as sensitivity analy-
sis. Meta- package in RStudio version 1.1.463 (2009– 
2018) was used.
RESULTS
Study, Participants and Proportion of 
Women
We included a total of 70 313 patients from 46 stud-
ies, published from January 2005 to October 2018. 
Baseline characteristics of patients are reported in 
Table 1.23– 68 Among the patients included in the analy-
sis, there were 35 691 women with a cumulative pro-
portion of 51.5% (95% CI, 50.2%– 52.7%) (Figure S2). 
Heterogeneity was high (I2=88.6%; 95% CI, 85.6%– 
90.9%]). No publication bias was found (Egger test P 
value 0.3362). The proportion of women dropped sig-
nificantly over time (P<0.0001) (Figure 1).
Type of Valves and Proportion of Women
Splitting the studies according to the percentage of 
women included, 4 categories were obtained: <50%, 
50% to 54%, 55% to 59%, and ≥60%. In the latter 
group of studies, balloon expanding valves were less 
implanted than the others. Conversely, self- expanding 
valves were highly implanted in those studies with 
higher proportion of women (Table S1). Mechanical ex-
panding valves were used less commonly in this meta- 
analysis (only 8 studies) and in most of cases was the 
only valve used.
Permanent Pacemaker Implantation 
Details
Pacemaker- related details in the selected stud-
ies are reported in Table  2.23– 68 Cumulative rate of 
PPI was 15.6% (95% CI, 13.3%– 18.3%) (Figure  2). 
Heterogeneity was high (I2=98.6%; 95% CI, 98.4%– 
98.7%]). No publication bias was found (Egger test 
P value 0.8759). The pooled analysis showed that 
women had lower risk for post- TAVI PPI than men 
(OR, 0.90; 95% CI, 0.84– 0.96 [P=0.0022]) (Figure 3). 
Heterogeneity was moderate (I2=38.5%; 95% CI, 
12.1%– 57.0%). No publication bias was found 
(Figure  S3), Egger test P value was 0.1234. Baujat 
plot (Figure  S4) showed that overall heterogeneity 
was becasuse of few studies but the leave- one- out 
analysis (Figure S5) showed that the overall estima-
tion was not driven by any single study.
Meta- Regression: Influence of Age, 
Ventricular Function, Balloon- Expandable 
TAVI, and Patient Risk
Meta- regression analysis showed no effect of age 
(P=0.874), and ventricular function (P=0.302) on dif-
ferent PPI rate between women and men (Figure S6A 
and S6B). Balloonexpandable TAVI showed a sig-
nificant effect of sex difference in terms of PPI rate 
(P=0.0061) (Figure S6C), meaning that the higher the 
percentage of balloon- expandable implanted, the 
lower the difference in terms of risk between women 
and men. Mean value of risk score reported in each 
study was used to define the cohort as at high or 
intermediate risk. Hence, intermediate risk was de-
fined as EuroSCORE (European System for Cardiac 
Operative Risk Evaluation) II between 4 and 9 or STS 
PROM (Society of Thoracic Surgeons Predicted Risk 
of Mortality) between 4 and 8. High risk was defined 
when Logistic EuroSCORE I was >20%, STS PROM 
was ≥8, or EuroSCORE II was >9. Finally, 30 studies 
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patients. No influence of pacemaker rate was found on 
the basis of cohort risk (P=0.9024) (Figure S6D).
DISCUSSION
This is the first meta- analysis to demonstrate the im-
pact of sex on new PPI after TAVI. Our study is derived 
from 46 studies reporting clinical outcomes in 70 313 
patients receiving TAVI. The most important findings 
of our study can be summarized as follows: (1) the 
proportion of women undergoing TAVI significantly de-
creases during the last 10  years; (2) female sex has 
10% lower risk for PPI after TAVI than men, with no 
influence of age or ventricular function (3) the use of a 
balloon- expandable valve in women reduces the ad-
vantage of female sex in term of PPI post- TAVI.
Nowadays, women represent more than 50% of 
the patients undergoing TAVI.69 Female patients eligi-
ble for TAVI have a lower burden of comorbidities.8,10,26 
Interestingly, we found that the proportion of women in-
volved in the studies decreased during the last 10 years. 
We found no explanation for such a result and this in-
formation deserves further investigation. However, even 
if our study showed a decreasing trend in female sub-
mitted to TAVI procedure, a longer life- expectancy of 
female sex might foresee that the proportion of women 
undergoing TAVI will increase in the future.70 Gathering 
these 2 aspects, we can reasonably extrapolate that 
women should be potential future low- risk patients who 
should benefit from TAVI. Therefore, decreasing com-
plications as PPI is decisive to define the best therapeu-
tic strategy for women with aortic stenosis.
Current evidence about the prognostic role of sex in 
outcomes after TAVI is poor, and the issue of atrioven-
tricular conduction disturbances requiring PPI across 
sexes is rarely debated.25,26,53 Recent studies showed 
favorable outcomes in female patients after TAVI,10,53,71 
without emphasizing the issue of post- operative PPI. 
Male sex was already identified as predictive factor for 
PPI after TAVI11 even if other investigations reported 
no differences in PPI across sexes.7,28 In this study, 
we found that women were 10% less at risk for PPI 
after TAVI procedure, confirming higher PPI rates in 
men reported by other studies.28,72,73 This sex- based 
difference in post- operative PPI is often related to the 
favorable baseline characteristics of the women under-
going TAVI, explaining the better outcomes in the female 
cohort.8,28 Nevertheless, data from feminine registry as 
WIN- TAVI74 investigated anatomic risk- factors specific 
to women in PPI after TAVI and showed that right cor-
onary cusp calcium volume was an independent pre-
dictor for PPI, while non- coronary cusp calcium has no 
incidence on atrio- ventricular conduction disturbances 
Figure 1. Forest plot pooling proportions of women 
according to year of publication.
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Table 2. Pacemaker- Related Details in the Selected Studies





Multivariate Predictors of 
PPI Association With PPI
D’Ancona et al23 Na 4 32 Age* Na
Buellesfled et al24 62.2% AVB/21.4% 
Others/16.3% bradycardia
3 28 Na Na
Humphries et al25 Na Na 5.5 Na Na
Hayashida et al26 Na Na 6.5 Na Na
De Carlo et al27 70% AVB/3% SSS/27% 
others
4 24 Lower MCV implantation 
below aortic annulus*  
RBBB*  
Left anterior hemiblock*  
Longer PR interval*
Na
Buja et al28 Na Na 19 Na Na





Gensas et al30 Na Na 25.2 Preexisting RBBB*  
Baloon predilatation*  
MCV use*
Na
Urena et al31 75.3% AVB/7.1% SSS/7.9% 
Bradycardia/9.6% others
3 15.4 Na PPI protective factor for the occurrence of 
unexpected (sudden or unknown) death*  
Negative effect on LVF over time*
Dizon et al32 79% AVB/7.3% SSS Na 8.8 Na PPI and 1- y mortality*
Mouillet et al33 Na Na 30.3 Na Na
Nazif et al34 79% AVB/17.3% SSS 3 8.8 Preexisting RBBB*  
Prosthesis to LV outflow tract 
diameter ratio*  
LV end- diastolic diameter*
Longer duration of hospitalization*  
Higher rates of repeat hospitalization and 
mortality or repeat hospitalization at 1 y*
Fadahunsi et al35 Na 3 6.7 Na PPI and higher mortality and composite of 
mortality or HF at 1 y*
Giustino et al36 Na Na 15.4 Na PPI+postprocedural aortic 
regurgitation=negative impact on survival and 
LVF recovery*  




Na Na 22.5 Na More LV outflow tract oversizing associated 
with higher PPI*
Gonska et al38 85.1% AVB/10.1% 
Bradycardia/4.8% others
Na 24.4 Na PPI without significant impact on survival or 
combined end point of major adverse events 
within 1 y*
Monteiro et al39 Na Na 20.1 Previous RBBB*  




Van Gils et al40 99% AVB/1% SSS 2 41 LOTUS valve*  
Higher BMI before TAVI*
RBBB at baseline associated with higher PPI*
Raelson et al41 82% AVB 3 9 Na Na
Dumonteil et al42 88.9% AVB/5.9% others 3 32 Baseline RBBB*  
LV outflow tract overstretch 
>10%*
Trend lower PPI rate at 30 d with shallower 
(≤5 mm) implant depth*
Chamandi et al43 76.7% AVB/5.6% SSS/3.1% 
Bradycardia/14.6% others
2 19.8 Na PPI higher rates of rehospitalization for HF 
and combined end point of mortality or 
hHFrehospitalization*  
PPI lesser improvement in LVF over time, 
particularly in patients with reduced LVF 
before TAVI*
Gaede et al44 90% AVB/8% SSS/2% 
Bradycardia
4 14.7 Preexisting RBBB*  
MCV prosthesis*
Predictors of lack of recovery of AVB  
Prior RBBB*  
Higher mean aortic valve gradient*  
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Multivariate Predictors of 
PPI Association With PPI
Bhardwaj et al45 Na Na 11.5 PPI with short- term reduction 
in QoL without long- term 
implications*
Na




Na 12.5 Na Na
Mangieri et al47 84% AVB/8.4% Bradycardia 0.3 8.8 Na Na
Gonska et al48 94.2% AVB/3.8% 
Bradycardia/2% others




Marzahn et al49 89% AVB/5.5% 
Bradycardia/4.1% SSS/1.4% 
others
Na 16.9 Na Na
Schewel et al50 Na Na 10.8 Na Na





Vejpongsa et al52 Na 2 9.9 Na Na
Sannino et al53 Na Na 18.4 Na Na
Doshi et al54 Na Na 25.5 Na Na
Nadeem et al55 Na Na 21.7 Na PPI more likely to have HF admissions*  
PPI trend toward increased mortality*
Pellegrini et al56 71.3% AVB/5.2% 
SSS/23.5% Bradycardia
Na 16.2 Increase in prosthesis 
oversizing*
Na
Pellegrini et al57 71.5% AVB/3.5% SSS/25% 
Bradycardia
Na 10 Higher EuroSCORE* Na
Costa et al58 84.8% AVB/4.1%SSS/11% 
others
Na 13 Na PPI associated with increased 6 y mortality*  
Baseline RBBB higher chance of being 
dependent at follow- up*
Dolci et al59 80%AVB/11% 
Bradycardia/9% others
4 13 Baseline RBBB*  
QRS width immediately after 
TAVI*
Na
Meduri et al60 90% AVB/6% 
Bradycardia/4% others
2 28.4 Baseline RBBB*  
Mean depth of valve 
implantation*
Medically treated diabetes mellitus in patients 
with LOTUS valve*
Husser et al61 80.2% AVB/16.4% 
Bradycardia/3.4% SSS
Na 39.2 Na If RBBB, lower PPI with Neo than Edwards 
Sapien 3*
Ahmad et al62 Na 1.3 6.3 Na Higher hemoglobin*  
29- mm Valve*  
Prior conduction defects*
Ahmad et al63 Na Na 5 Na Na
Cresse et al64 Na 4 6.7 Na RBBB, LBBB, △PR >40 ms associated with 
PPI*
Wang et al65 Na Na 7.7 Na Na
Maeno et al66 77.9% AVB/11.5% 
SSS/10.6% Bradycardia
Na 15.8 Na Na
Du et al67 89.5% AVB 8.7 14.8 Na Na
Shivamurthy et al68 Na Na 9.8 Na Na
Values are number (percentage), mean=SD, or median (interquartile range) as appropriate. △ indicates change; AF, atrial fibrillation; AVB, atrioventricular 
block; BMI, body mass index; Edwards Sapien 3 valve (Edwards Lifesciences); EuroSCORE, European System for Cardiac Operative Risk Evaluation; HF, heart 
failure; LBBB, left bundle branch block; LOTUS valve (Boston Scientific Corporation); LV, left ventricular; LVF, left ventricular function; MCV, Medtronic CoreValve 
(Medtronic); Na, not available; PPI, permanent pacemaker implantation; QoL, quality of life; RBBB, right bundle branch block; SSS, sick sinus syndrome; and 
TAVI, transcatheter aortic valve implantation.
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leading to PPI. Moreover, women with severe aortic 
stenosis have smaller aortic root dimensions com-
pared with men, even after correction for body size 
and height.75 The use of smaller devices and the lower 
need for eventual procedural balloon dilatation be-
cause of the smaller aortic root dimensions can explain 
Figure 2. Forest plot pooling rate of postprocedure pacemaker implantation in 46 studies.23– 68
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the lower rate of PPI in women,76 making women less 
likely to undergo PPI post- TAVI, independently from 
age or ventricular function, as highlighted in this study.
Interestingly, we found that using a balloon- 
expandable valve could attenuate the advantage 
of women on post- operative PPI, reaching thus the 
Figure 3. Forest plot comparing the effect of sex on the rate of postprocedure pacemaker implantation.23– 68
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same risk as men. Generally, self- expandable de-
vices are more described as predictive factors for 
PPI after TAVI than balloon- expandable devices, 
also in women.11,77 However, the recent SOLVE-
TAVI (Second- Generation Self- Expandable Versus 
Balloon- Expandable Valves and General Versus Local 
Anesthesia in TAVI) trial78 showed that newer gen-
eration of self- expandable and balloon- expandable 
valve are equivalent in postoperative PPI, emphasiz-
ing that individual valve anatomy can lead to specific 
preferences in some patients. Thiele et al78 reported 
a higher rate of postoperative PPI, probably related to 
the restrictive use of only 2 specific devices (Evolut R 
and Sapien 3), while the heterogeneity of the devices 
reported in this meta- analysis may have flattened the 
rate of PPI, explaining a lower rate of such outcome. 
Smaller annulus size in women can create a likely 
higher degree of oversizing, a potentially condition 
for higher postoperative rate of PPI, especially with 
balloon- expandable valves.56
Limitations
This investigation presents some limitations. First, 
although the present meta- analysis is based on 
published studies, publication bias still remains a 
weakness. Furthermore, on the 37 retrospective 
studies and the 9 prospective studies included, only 
1 study was randomized. Second, the heterogeneity 
among studies was moderate, but no particular study 
determined the final results, which give us confidence 
in our statistic model. Nevertheless, no standard ap-
proach was defined with respect to the indications 
for PPI among studies and this heterogeneity should 
also be a source of variability in rate of PPI after TAVI. 
Third, lower sample studies were excluded from the 
final analysis, which may let us miss some information. 
Fourth, all studies did not include both in- hospital PPI 
and PPI after discharge to 30 days. Finally, this was 
a study- level meta- analysis. An analysis of individual 
patient data may provide further insights.
CONCLUSIONS
Female patients undergoing TAVI are at lower risk for 
PPI after TAVI, without influence of age or ventricu-
lar function. Balloon- expandable devices blunt this 
advantage in favor of women. Further studies are re-
quired to reduce the need for postoperative PPI, as 
well as further developments regarding prosthesis de-
sign and patient selection in order to offer a patient- 
tailored approach.
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Table S1. Proportion of prosthesis used by percentage of females included in each study. 
 Percentage of female  
Type of 
prosthesis 
Female <50% Female 50-54% Female 55-59% Female≥60% p-value 
BE  68.2% (58.4- 76.6) 65.2% (43.7- 81.9) 54.4% (33.9- 73.6) 45.1% (12.2- 82.9) <0.001 
SE 29.6% (21.5- 39.2) 14.2% (6.6- 27.9) 41.1% (24.1- 60.7) 54.9% (17.1- 87.7) 0.0455 
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Figure S2. Forest plot pooling proportion of females in 46 studies (23-68).  
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Figure S4. Baujat plot.  
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Figure S5. Forest plot leave one-out analysis comparing the effect of sex on the rate of 
post-procedure pacemaker implantation (23-68).  
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Figure S6. Bubble plots: influence of age on risk for post procedure pacemaker 
implantation on the basis of sex (Panel A); influence of ventricular function on risk for post 
procedure pacemaker implantation on the basis of sex (Panel B); influence of balloon 
expandable prosthesis on risk for post procedure pacemaker implantation on the basis of sex 
(Panel C); influence of the patient risk on risk for post procedure pacemaker implantation on 
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